Brainsgate

BrainsGate is developing a novel neurostimulation technology, for the Spheno-Palatine Ganglion (SPG), which can dialate cerebral blood vessels, increasing blood flow to the brain. The leading application for this technology is treatment of acute ischemic stroke in a 24 hour window, where the company is in the midst of a pivotal (phase-III) multi-center, multi-national trial with results expected in late 2011. Additional applications include vascular dementia. Among the company investors are Johnson & Johnson and Boston Scientific.